Free Trial
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

$1.91
0.00 (0.00%)
(As of 09/17/2024 ET)

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Key Stats

Today's Range
$1.88
$1.96
50-Day Range
$1.64
$2.01
52-Week Range
$1.25
$32.42
Volume
226,567 shs
Average Volume
513,610 shs
Market Capitalization
$55.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25
Consensus Rating
Hold

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 28th Percentile

Aerovate Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 857th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aerovate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aerovate Therapeutics has received no research coverage in the past 90 days.

  • Read more about Aerovate Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.74) to ($0.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aerovate Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aerovate Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aerovate Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aerovate Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.49% of the float of Aerovate Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aerovate Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aerovate Therapeutics has recently increased by 9.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aerovate Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aerovate Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.49% of the float of Aerovate Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aerovate Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aerovate Therapeutics has recently increased by 9.48%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aerovate Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Aerovate Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for AVTE on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aerovate Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.90% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Aerovate Therapeutics' insider trading history.
Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTE Stock News Headlines

Bill Gates’ Next Big Thing: “Exegesis AI”
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.
See More Headlines

AVTE Stock Analysis - Frequently Asked Questions

Aerovate Therapeutics' stock was trading at $22.63 at the start of the year. Since then, AVTE shares have decreased by 91.6% and is now trading at $1.91.
View the best growth stocks for 2024 here
.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its earnings results on Monday, August, 12th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.10.

Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

Aerovate Therapeutics' top institutional shareholders include Atlas Venture Life Science Advisors LLC (6.24%), Deerfield Management Company L.P. Series C (4.90%), Affinity Asset Advisors LLC (0.69%) and SG Americas Securities LLC (0.62%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Marinus Verwijs and Timothy P Noyes.
View institutional ownership trends
.

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/12/2024
Today
9/17/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVTE
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+17.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-75,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
21,645,000
Market Cap
$55.05 million
Optionable
Optionable
Beta
1.03
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AVTE) was last updated on 9/17/2024 by MarketBeat.com Staff
From Our Partners